As part of our ongoing effort to bring you reports of interesting new studies, we have added a study that evaluated the effectiveness and safety of rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and with comorbid type 2 diabetes mellitus.
Independent expert commentary is provided by Associate Professor Amerena, a Cardiologist at Barwon Health with joint appointments in the Department of Clinical and Biomedical Sciences at the University of Melbourne and the Department of Epidemiology and Preventive Medicine at Monash University.
Please login below to download this issue (PDF)